Prescribing InformationPatient Tool Kit
Logo
About SEM-P?Mechanism of ActionProven ResultVideo Library
Prescribing InformationPatient Tool Kit
Logo
About SEM-P?Mechanism of ActionProven ResultVideo Library

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

Cardiovascular Disease

kidney Disease

Lung Disease

Liver Disease

GLP-1 RA as first line treatment option regardless of metformin use, individual A1c target or baseline A1c

ADA[1]

AACE[2]

AHA[3]

Heart Icon

In patients with established Atherosclerotic Cardiovascular Disease (ASCVD)

BMI Icon

In patients with high BMI

HbA1c Icon

In patients with raised HbA1c

Use of GLP-1 RA Medications in the Management of Type 2 Diabetes[4]

Ra Medication Illustration

Meet Mr. Ahmed*

Mr. Ahmed*
Age:51 years
Occupation:Software Engineer
Lifestyle:Sedentary; long work hours and poor dietary habits
Diagnosis:Type 2 Diabetes Mellitus (Uncontrolled on Dual OADs)
Comorbidities:Obesity, Lifestyle related metabolic risk
Parameters
FPG170 mg/dL
PPG250 mg/dL
HbA1c8.4%
BMI30 kg/m²
Clinical Challenges:
  • iconPersistent hyperglycemia despite dual OAD therapy
  • iconWeight gain
  • iconDifficulty maintaining diet and exercise adherence
  • iconIncreased cardiovascular risk
Therapeutic Goal
  • Achieve meaningful HbA1c reduction and weight loss
  • Reduce risk of hypoglycemia
  • Support sustainable lifestyle improvement
Mr. Ahmed*

Meet Mr. Ahmed*

Ms. Samina*

Meet Ms. Samina*

Ms. Saira*

Meet Ms. Saira*

Mr. Adeel*

Meet Mr. Adeel*

Mr. Hamza*

Meet Mr. Hamza*

Ms. Rabia*

Meet Ms. Rabia*

Mrs. Huma*

Meet Mrs. Huma*

Dosing Schedule

Dosage pen
DoseFrequencyDuration
Initiate with0.25 mg
Once weeklyContinue for 4 weeks
Escalate & Maintain to0.5 mg
Once weeklyContinue for 4 weeks
Escalate & Maintain to1.0 mg
Once weeklyContinue till doctor prescription
Maintain at2.0 mg
Once weeklyContinue till doctor prescription

If you need more information contact us: 021-111-455-455

Biosimilarity vs Innovator Brand

Biosimilar Approval Requirements

Analytical Comparison

In Vitro Biosimilarity Studies

Non Clinical Studies

Phase I Trial N=66, 56 Days

Clinical Pharmacology

Clinical PK Studies

Comparative Clinical Study

Phase III Trial N=476, 464 Days

Structural homology to human GLP-1 RA

Comparable HbA1c reduction to innovator brand

Comparable weight reduction to innovator brand

sem-p Medinice
  • Evidence-Based Biosimilar Semaglutide for Safe & Effective Therapy. [13]
  • Powerful HbA1c reduction up to 1.9%. [14]
  • Significant weight reduction of up to 14.9% of body weight. [15]
  • Achieved steatohepatitis resolution without fibrosis worsening up to 62.9%. [16]

References

[1] ADA Guidelines 2025.

[2] AACE2024 Guidelines

[3]AHA Guidelines 2024

[4]ADA Guidelines 2025

[5] Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet Diabetes & Endocrinology [Internet]. 2021 Sep;9(9):563–74.

[6] Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025 Apr 30;392(21).

[7] Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024 May 24; 390(21):2011-2023. doi:10 1056/NEJMoa2403347.

[8] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine [Internet]. 2016 Nov 10;375(19):1834–44.

[9]Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, obesity-related heart failure and type 2 diabetes. N Engl Hovingh GK, et al. Semaglutide in patients with J Med. 2024 Apr 6;390(15):1394-407

[10] Kosiborod MN et al. N Engl J Med 2023;389:1069–84

[11] Kosiborod MN et al. N Engl J Med 2024;390:1394–407

[12] Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024 Oct 31;391(17):1573–83

[13] Biosimilarity studies conducted by manufacturer of semaglutide

[14] Marso SP et al. NEJM. 2016;375:1834–1844

[15]Wilding JPH et al. NEJM. 2021;384:989–1002

[16] Newsome PN et al. NEJM. 2021;384:1113–1124

Abbreviations:

  • FPG: Fasting Plasma Glucose
  • PPG: Post Prandial Glucose
  • HbA1c: Glycated Hemoglobin 
  • BMI: Body Mass Index
  • OAD: Oral Anti-Diabetic Drug
  • ADA: American Diabetes Association
  • ALT: Alanine Aminotransferase
  • CKD: Chronic Kidney Disease
  • UACR: Urine Albumin-to-Creatinine Ratio
  • eGFR: Estimated Glomerular Filtration Rate
  • ASCVD: Atherosclerotic Cardiovascular Disease
  • HFpEF: Heart Failure with Preserved Ejection Fraction
  • HF: Heart Failure
  • DM: Diabetes Mellitus
  • KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire-Clinical Score
Image